<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, more than 100 chemotherapeutic drugs are known and are used either as a single entity or in combination of two or more to treat cancer patients. Cyclophosphamide (CPA) is an alkylating agent that belongs to the class of oxazaphosphorines. WHO listed CPA as one of the most successful chemotherapeutic drugs on WHO Model List of Essential Medicines (
 <xref rid="ref31" ref-type="bibr">WHO, 2015</xref>). Despite its immunosuppressant and genotoxic properties, CPA has been extensively used to treat a variety of malignancies such as carcinoma of the breasts, lungs, lymphomas, leukemias, and myeloma (
 <xref rid="ref28" ref-type="bibr">Tripathi and Jena, 2008</xref>). Two active metabolites of CPA, namely acrolein and phosphoramide mustard formed by the action of liver microsomal enzyme cytochrome P
 <sub>450</sub> are responsible for the anticancer potential and associated genotoxic effects of this drug (
 <xref rid="ref3" ref-type="bibr">Colvin and Hait, 2010</xref>; 
 <xref rid="ref14" ref-type="bibr">Kour et al., 2017</xref>). The Organization for Economic Co-operation and Development (OECD, 2014) has recommended the use of CPA as a positive control for 
 <italic>in vitro</italic> evaluation of mammalian chromosomal aberrations (CAs) and in genetic toxicity studies.
</p>
